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Novel therapies capable of reducing myocardial infarct (MI) size when administered prior to reperfusion
are required to prevent the onset of heart failure in ST-segment elevation myocardial infarction (STEMI)
patients treated by primary percutaneous coronary intervention (PPCI). Experimental animal studies have
demonstrated that mineralocorticoid receptor antagonist (MRA) therapy administered prior to reperfusion can
reduce MI size, and MRA therapy prevents adverse left ventricular (LV) remodeling in post-MI patients with LV
impairment. With these 2 beneﬁts in mind, we hypothesize that initiating MRA therapy prior to PPCI, followed
by 3 months of oral MRA therapy, will reduce MI size and prevent adverse LV remodeling in STEMI patients.
The MINIMISE-STEMI trial is a prospective, randomized, double-blind, placebo-controlled trial that will recruit
150 STEMI patients from four centers in the United Kingdom. Patients will be randomized to receive either an
intravenous bolus of MRA therapy (potassium canrenoate 200mg) or matching placebo prior to PPCI, followed
by oral spironolactone 50 mg once daily or matching placebo for 3 months. A cardiac magnetic resonance
imaging scan will be performed within 1 week of PPCI and repeated at 3 months to assess MI size and LV
remodeling. Enzymatic MI size will be estimated by the 48-hour area-under-the-curve serum cardiac enzymes.
The primary endpoint of the study will be MI size on the 3-month cardiac magnetic resonance imaging scan.
TheMINIMISE STEMI trial will investigate whether early MRA therapy, initiated prior to reperfusion, can reduce
MI size and prevent adverse post-MI LV remodeling.
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Introduction
Coronary artery disease is one of the leading causes of death
and disability worldwide,1 resulting in an estimated 7.3
million deaths per year.2 Despite major advances in the field
of interventional cardiology, the mortality of ST-segment
elevation myocardial infarction (STEMI) remains high; in-
hospital mortality is approximately 5% to 6%, increasing to 7%
to 18% at 1 year.3 In a large US registry consisting of 606 500
patients with acute myocardial infarction, heart failure (HF)
was identified in 20.4% of individuals at admission, with a
further 8.6% developing HF during the hospitalization itself.4
The onset of HF post-STEMI is closely related to the final
myocardial infarct (MI) size. For patients presenting with
an acute STEMI, the most effective therapy for limiting
MI size, preserving left ventricular (LV) function, and
reducing the onset of HF is timely reperfusion using primary
percutaneous coronary intervention (PPCI).5–8
Myocardial Reperfusion Injury as a Neglected Therapeutic
Target
Although timely reperfusion is required to salvage viable
myocardium in STEMI patients, the restoration of coronary
blood flow in the infarct-related artery has the potential in
itself to induce cardiomyocyte death, a phenomenon that
has been termed myocardial reperfusion injury and can
contribute up to 50% of the final MI size.9 Therefore, novel
therapies capable of protecting the heart from myocardial
reperfusion injury may allow one to maximize the benefits
of myocardial reperfusion in terms of MI size reduction.
In this regard, the mineralocorticoid receptor antagonist
(MRA) spironolactone may be beneficial.
Mineralocorticoid Receptor Antagonist Therapy
Aldosterone, a mineralocorticoid receptor agonist, is synthe-
sised primarily in the adrenal gland and is part of the renin-
angiotensin-aldosterone system. It is known to regulate a
number of pathophysiological pathways important to post-
MI HF, including inhibition of nitric oxide activity,10 acute
endothelial dysfunction,11 increased vascular tone,12 vas-
cular smooth muscle cell and cardiomyocyte necrosis,13,14
myocardial hypertrophy and fibrosis,15,16 apoptosis,17 and
unfavorable LV remodeling.18 Consequently, a number of
landmark clinical studies have highlighted the significant
benefits of aldosterone antagonist therapy on clinical out-
comes post-MI.19–21
Mineralocorticoid Receptor Antagonist Therapy to Target
Myocardial Reperfusion Injury
Experimental preclinical data have demonstrated that
administering MRA therapy by a clinically relevant
regimen, using either intravenous potassium canrenoate
(a compatible metabolite of spironolactone) or eplerenone,
after a sustained episode of myocardial ischemia and 5
minutes prior to reperfusion, protected the heart against
myocardial reperfusion injury and reduced MI size by 40%
to 50% in murine, rat and rabbit in vivo models of MI.22 An
earlier experimental study had reported a cardioprotective
effect with the administration of eplerenone prior to the
index ischemic event in the isolated perfused rat heart.23 A
more comprehensive review of the cardioprotective effects
of MRA therapy has been summarized in the review by van
den Berg et al.24
Therefore, in this study we aim to combine the acute
benefit of MRA therapy to reduce reperfusion injury and
its benefit on preventing LV remodeling after 3 months of
oral therapy. We hypothesize that early intravenous MRA
therapy administered prior to reperfusion followed by 3
months of oral MRA therapy can reduce MI size and reduce
adverse LV remodeling in STEMI patients.
Methods
Overall Study Design
The MINIMISE-STEMI trial (https://clinicaltrials.gov,
NCT01882179) is a proof-of-concept randomized clinical
trial designed to investigate whether MRA therapy initiated
prior to reperfusion and continued for 3 months can reduce
MI size and prevent adverse LV remodeling at 3 months
in STEMI patients treated by PPCI. It is a prospective,
randomized, double-blind, placebo-controlled clinical trial
that will recruit 150 patients through 4 tertiary care hospitals
in the United Kingdom. The study will be conducted
in accordance with the Declaration of Helsinki and has
been approved by the National Research Ethics Service. All
patients will provide informed written consent.
Overall Objective
The main objective will be to investigate whether MRA
therapy initiated prior to PPCI and continued for 3 months
reduces MI size and prevents adverse LV remodeling in
STEMI patients.
Study Protocol
On immediate arrival at the hospital, patients presenting
with an acute STEMI will be asked to give brief informed
written consent to enter the MINIMISE-STEMI trial and
basic eligibility will be assessed. At coronary angiography,
eligibility of inclusion into the trial (ie, proximal coronary
artery occlusion and serum potassium (K+) <5.0 mmol/L
and estimated glomerular filtration rate (eGFR) >30
mL/min/1.73m2) will be confirmed and patients will then
be randomized to receive either MRA therapy or matching
placebo. A detailed informed written consent will then be
obtained on the ward following the PPCI procedure, within
24 hours after obtaining brief informed written consent, but
before the patient is started on oral study medication. Blood
tests will be taken to measure high-sensitivity troponin T
(hsTropT) and creatine kinase-MB isoenzyme (CK-MB) at
the following time points pre-PPCI and 6, 12, 24, and 48 hours
post-PPCI. In the first week following hospital admission, the
patient will undergo a cardiovascular magnetic resonance
imaging (MRI) scan (cardiovascular magnetic resonance
[CMR], and this will be repeated 3 months later, after which
the study ends. The overall study protocol is provided in the
Figure 1.
Patient Eligibility Criteria
All consecutive patients presenting with presumed acute
STEMI in the 4 participating centers will be screened for
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Figure 1. Overall patient pathway. Abbreviations: CMR, cardiac magnetic resonance imaging; IV, intravenous; LVEF, left ventricular ejection fraction; MRA,
mineralocorticoid receptor antagonist; PCI, percutaneous coronary intervention; STEMI, ST-segment elevation myocardial infarction; TIMI, Thrombolysis In
Myocardial Infarction.
eligibility. The inclusion and exclusion criteria are listed in
Table 1.
Randomization and Treatment Allocation
Eligible patients will be randomized via a Web-based ser-
vice (https://www.sealedenvelope.com) in a 1:1 manner
to either MRA therapy or matching placebo. Random-
ization will be stratified by recruiting site. The patient,
interventional cardiologist, caregivers, and data collector
will be blinded to the treatment allocation. The study drug
or placebo will be administered by the nonblinded research
investigator.
Study Drug and Placebo
MRA Therapy: Patients randomized to MRA therapy will
receive an intravenous bolus of potassium canrenoate
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Table 1. Patient Inclusion and Exclusion Criteria
Inclusion criteria for entry into trial (assessed on arrival at hospital)
Patients age>18 years
Patients presenting with acute STEMI and eligible for PPCI (as assessed by 12-lead ECG; ST-segment elevation ≥2 mm [0.2 mV] in ≥2 contiguous
precordial leads or ≥1mm [0.1 mm] in ≥2 adjacent limb leads)
Presentation within 12 hours after symptom onset
Inclusion criteria for randomization (assessed in cardiac catheterization laboratory)
Angiographically proven proximal occlusion (TIMI: 0) of a major coronary vessel (LAD, LCX, RCA)
Normal serum K+ (<5.0 mmol/L)
Exclusion criteria for entry into trial (assessed on arrival at hospital)
Patients with known LVEF ≤40%
Participation in another trial
Cardiogenic shock (positive shock index OR need for catecholamine support OR SBP<90 mm Hg)
Killip class>2
Prior MI
Known compromised renal function (eGFR<30 mL/min/1.73 m2) or K+ >5.0 mmol/L
Current treatment with MRAs
Current treatment with cyclosporine
Pregnant or lactating females
Females of childbearing potential and males must be willing to use an effective method of contraception (hormonal or barrier method of birth control;
abstinence) from the time consent is signed until visit 5, as per the guidance in the patient information leaﬂet
Allergies to IMP or its excipients
Known contraindication to CMR such as signiﬁcant claustrophobia, severe allergy to gadolinium chelate contrast, presence of CMR-contraindicated
implanted devices (eg, pacemaker, ICD, CRT device, cochlear implant), imbedded metal objects (eg, shrapnel), or any other contraindication for CMR
Once the current sCr is known, patients with severely compromised renal function (eGFR<30 mL/min/1.73 m2) will also be excluded
Patients with known porphyria
Patients with signiﬁcant liver dysfunction (INR>2)
Patients with known contraindications to treatment with spironolactone
Abbreviations: CMR, cardiovascular magnetic resonance imaging; CRT, cardiac resynchronization therapy; ECG, electrocardiogram; eGFR, estimated
glomerular ﬁltration rate; ICD, implantable cardioverter-deﬁbrillator; IMP, investigational medicine product; INR, international normalized ratio; K+,
potassium; LAD, left anterior descending coronary artery; LCX, left circumﬂex coronary artery; LVEF, left ventricular ejection fraction; MI, myocardial
infarction; MRA, mineralocorticoid receptor antagonist; PPCI, primary percutaneous coronary intervention; RCA, right coronary artery; SBP, systolic blood
pressure; sCr, serum creatinine; STEMI, ST-elevation myocardial infarction; TIMI, Thrombolysis In Myocardial Infarction.
(200 mg, in keeping with the dose used initially by Hayashi
et al25 and subsequently in the Aldosterone Blockade Early
After Acute Myocardial Infarction [ALBATROSS] trial)26
followed by oral spironolactone 25 mg once daily for 2
weeks and then 50 mg once daily for the remaining 10
weeks, after which the MRA therapy will be stopped. Serum
K+ will be checked at 2 and 4 weeks. Spironolactone will
only be uptitrated to 50 mg after 2 weeks if the serum K+
is ≤5.0 mmol/L. If the serum K+ is 5.1 to 5.5 mmol/L, 25
mg spironolactone will be maintained, and if the K+ is >5.5
mmol/L, spironolactone will be discontinued.
Matching Placebo: Patients randomized to control will
receive an intravenous bolus of normal saline followed by
placebo control tablets for the 3 months, after which the
placebo will be stopped. Serum K+ will be checked at 2 and
4 weeks.
Optimal Heart Failure Treatment
The study protocol will ensure optimal medical therapy
for all study participants according to current practice
guidelines.3,27–29 Therefore, patients with a left ventricular
ejection fraction (LVEF) ≤40% on the initial CMR scan and
evidence of HF or who have diabetes mellitus (DM) will
be started on open-label eplerenone according to current
practice guidelines. These patients will be included in the
intention-to-treat analysis.
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Cardiac Magnetic Resonance Protocol and Analysis
Each patient recruited into the MINIMISE-STEMI trial will
have 2 CMR scans, the first being performed in the week
following hospital admission and the second performed at 3
months. Training in the CMR protocol will be provided to
each recruiting site. All CMR scans will be analyzed by an
independent MRI CoreLab at University College London.
The primary endpoint of MINMISE-STEMI trial will be
MI size on the 3-month CMR scan (measured as the mass
of late gadolinium enhancement (LGE) and expressed as a
percentage of the LV mass). The CMR parameters that will
be determined for the first CMR scan:
1 LVEF and indexed LV end-systolic and end-diastolic
volumes and mass using short-axis steady-state free-
precession cine imaging.
2 MI size, measured by the mass of LGE (10 minutes
after administration of contrast) on CMR expressed
as a percentage of LV mass.
3 Area at risk (AAR), measured as the increase in T2
signal on-T2 weighted images or T2 mapping, both
of which have been validated against conventional
measures of the AAR.30–32 The AAR will also be
estimated using the modified Bypass Angioplasty
Revascularization Investigation Myocardial Jeopardy
Index (BARI) and Alberta Provincial Project for
Outcome Assessment in Coronary Heart Disease
(APPROACH) angiography scores.33
4 Myocardial salvage index = AAR − MI size/AAR.
The myocardial salvage index (using T2-weighted
CMR and LGE) has been demonstrated to predict
prognosis post-PPCI.34
5 The incidence and extent of microvascular obstruc-
tion (hypo-enhancement on LGE 20 minutes after
administration of contrast).
6 The incidence and extent of intramyocardial hemor-
rhage (hypo-enhancement on Siemens T2* mapping
sequence).
The CMR parameters that will be determined for the
second CMR scan, at 3 months:
1 LVEF and indexed LV end systolic and diastolic
volumes, wall thickness, and mass using short-
axissteady-state free-precession cine imaging.
2 Final MI size, which represents the primary endpoint,
measured by the mass of LGE and expressed as a
percentage of the LV mass.
The CMR images will be analyzed by 2 experienced
operators blinded to the treatment allocation and clinical
outcome. Datasets will be reported in consensus, and
advice from a third MRI operator will be sought in cases
of disagreement (>5 g difference in infarct size between
operators based on the limits of agreement for interobserver
variability with the Otsu automated thresholding technique
from Vermes et al).35 Left ventricular volumes and mass
measurements will be calculated conventionally using
dedicated software (CVI42 software, version 5.0.3; Circle
Cardiovascular Imaging, Calgary, AB, Canada), with
papillary muscles considered as part of the LV myocardium.
Analysis of MI size and extent of myocardial edema will
be performed using an in-house macro written in ImageJ.36
The epicardial and endocardial borders will be manually
traced and the areas of LGE will be quantified using
the semiautomated Otsu detection method, as previously
validated by Vermes et al.35 Any dark areas of hypo-
enhancement (microvascular obstruction ± intramyocardial
hemorrhage) within the area of LGE will be included in the
infarct area.37
Study Endpoints
The primary endpoint of the MINIMISE-STEMI study will
be MI size quantified by LGE cardiac MRI performed at
3 months following hospital admission. The secondary
endpoints are listed in Table 2. The safety endpoints will
include major adverse cardiac events and side effects
from MRA therapy (cardiovascular death, nonfatal MI,
revascularization, hospitalization for HF, hyperkalemia,
deterioration of kidney function, and need for dialysis;
Table 3). Major adverse cardiac events will be reported
after 3 months.
Statistical Analysis
A sample size of 50 in each group will have 80% power
to detect a difference in means of 8.0 g infarct mass as
assessed by MRI (the difference between a Group 1 mean,
μ1, of 40.0 g, and a Group 2 mean, μ2, of 32.0 g), assuming
that the common SD is 14.0 g infarct mass38 using a 2-group
t test with a 0.05 2-sided significance level. However, we
anticipate that about 10% of patients in the control group
will have LVEF ≤40%, in which case they will receive the
trial treatment as a matter of standard care. To allow for
this dilution of the treatment effect, we have increased the
sample size in each group to 62. If we further assume
an attrition rate of approximately 15%, then 75 patients
per group will be needed, for a total trial size of 150
patients.
Statistical analysis will be performed using SAS version
9.3 (SAS Inc., Cary, NC). The Fisher exact test will be
used to compare categorical variables. Continuous variables
will be compared with a mixed-effects model to account
for repeated measures. Primary data analysis will be
performed in the intention-to-treat population, regardless
of the treatment that was actually received. The results of
as-treated analyses for primary and secondary endpoints
will also be calculated. Time-to-event analyses (secondary
clinical endpoints), based on all available follow-up data, will
be performed with the use of Kaplan-Meier estimates and
be compared between groups with the use of the log-rank
test. A generalized linear model will be used to calculate risk
ratios in the subgroup analyses and to test for interactions.
After 75 patients have completed the trial, an interim
analysis will be performed by the study statistician for safety
reasons. The results will be evaluated by the data-monitoring
committee.
Data Management, Funding and Logistics
University College London is the sponsor of the trial. Data
will be collected by a paper case report form and entered onto
the Web-based electronic RedCap database. An independent
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Table 2. Secondary Outcome Measures
Markers of myocardial reperfusion injury (myocardial blush grade, TIMI ﬂow post-PPCI, ST-segment resolution at 90 minutes post-PPCI)
Microvascular obstruction on CMR
Myocardial salvage (AAR by T2 imaging−ﬁnal infarct size)
Acute myocardial infarct size (serum biomarkers and CMR on day 2–7)
Serum biomarkers (hsTropT, CK-MB) at the following time points; 0, 6, 12, 24, and 48 hours post-PCI (±1 hour)
LV remodeling on 3-month CMR scan (index LVEDV and LVESV, LVEF, and LV mass and wall thickness)
Clinical outcome measures: CV death, nonfatal MI, revascularization, hospitalization for HF, hyperkalemia, deterioration of kidney function, need for
dialysis
Abbreviations: AAR, area at risk; CK-MB, creatine kinase MB isoenzyme; CMR, cardiovascular magnetic resonance imaging; CV, cardiovascular; HF, heart
failure; hsTropT, high-sensitivity troponin T; LV, left ventricular; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction;
LVESV, left ventricular end-systolic volume;MI,myocardial infarction; PPCI, primary percutaneous coronary intervention; TIMI, Thrombolysis InMyocardial
Infarction.
Table 3. Deﬁnitions of Safety Endpoints
CV death Death due to a known CV cause or where the cause of death is unknown (ie, where no other cause of death has been
identiﬁed from the medical history or an autopsy)
Nonfatal MI Detection of rise and or fall of cardiac biomarkers with ≥1 value>99th percentile of the upper reference limit
together with evidence of myocardial ischemia with≥1 of the following: symptoms of ischemia; new ST-T changes
or new LBBB or development of pathological Q waves on the ECG; imaging evidence of new loss of viable
myocardium or new regional wall-motion abnormality
Revascularization Any repeat PCI or CABG with or without valve within the ﬁrst year postsurgery
Hospitalization for HF Hospital admission of ≥24-hour stay. HF will be judged to be present on symptoms (≥1 of the following: new or
worsening dyspnea, orthopnea, or paroxysmal nocturnal dyspnea, or increasing fatigue/worsening exercise
tolerance) and signs (1 of the following: new pulmonary edema by chest X-ray in the absence of a noncardiac
cause, crepitations believed to be due to pulmonary edema, and use of loop diuretics to treat presumed
pulmonary congestion).
Hyperkalemia Serum K+ level>5.5 mmol/L
Deterioration of renal function sCr increase of>25% from baseline
Stroke Stroke will be deﬁned as a focal, central neurological deﬁcit lasting>72 hours that results in irreversible brain
damage or body impairment.
Abbreviations: CABG, coronary artery bypass grafting; CV, cardiovascular; ECG, electrocardiography; HF, heart failure; K+, potassium; LBBB, left bundle
branch block; MI, myocardial infarction; PCI, percutaneous coronary intervention; sCr, serum creatinine.
data-monitoring committee (IDMC) will be installed to
monitor the progress of the study as well as any safety
concerns. All expected or unexpected adverse events will
be reviewed continuously by the investigators, the sponsor
and the IDMC according to the sponsor’s regulations. The
MINIMISE-STEMI trial is funded by the Rosetrees Trust
and the National Institute for Health Research (NIHR)
Clinical Research Network.
Study Timeline
Although the study has been open to recruitment since
November 2013, recruitment has been slow, but it is
expected to improve with the recent expansion to a fourth
center. We currently have 24 patients enrolled in the study,
and we anticipate to recruit a further 51 patients over the
next 6 months (July 2015), when an interim analysis will be
performed. We plan to complete recruitment in February
2016, with the last patient having the 3-month CMR scan in
May 2016 and the results of the study available in August
2016.
Discussion
The MINIMISE-STEMI trial is designed to investigate
whether MRA therapy using spironolactone initiated prior to
reperfusion and continued for 3 months can reduce MI size
and prevent adverse LV remodeling at 3 months in STEMI
patients treated by PPCI, when compared with placebo
control. The Eplerenone Post-AMI Heart Failure Efficacy
and Survival (EPHESUS) study demonstrated a 15% relative
risk reduction in death at 16 months in AMI patients with
LVEF <40% and HF signs administered oral eplerenone
therapy (initiated 3–14 days post-MI) when compared
with matching placebo.19 The beneficial effects of oral
MRA therapy have been confirmed in subsequent clinical
trials.20,21,39 The American27 and European29 guidelines now
recommend eplerenone for all patients presenting with an
AMI, LV dysfunction (LVEF ≤40%), and HF symptoms or
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DM. Therefore, it is anticipated that about 10% of the trial
participants will meet these criteria and will go on open-label
MRA therapy, and this has been taken into account in the
sample-size calculation.
Hayashi et al25 investigated the early use of spironolac-
tone immediately post percutaneous transluminal coronary
angioplasty in patients with anterior STEMI and showed a
reduction in postinfarct LV remodeling when used in com-
bination with an angiotensin-converting enzyme inhibitor.
Recently, the Early Eplerenone Treatment in Patients With
Acute ST-Elevation Myocardial Infarction Without Heart
Failure (REMINDER) trial investigated the effect of initiat-
ing oral eplerenone therapy 12 to 24 hours following STEMI
admission (in the absence of HF) and reduced the incidence
of patients with elevated serum brain natriuretic peptide/N-
terminal-pro-brain natriuretic peptide at ≥1 month after
randomization, when compared with placebo.40 The ALBA-
TROSS trial is investigating the effect of MRA therapy
initiated within 72 hours of symptom onset in patients with
either non–ST-segment elevation myocardial infarction or
STEMI (regardless of HF status) on the 6-month primary
combined endpoint of death, resuscitated cardiac arrest,
significant ventricular arrhythmia, class IA indication for
an implantable defibrillator device, and new or worsening
HF. In that study, the MRA therapy will comprise an IV
bolus of potassium canrenoate (200 mg) followed by a
daily 25-mg dose of spironolactone for 6 months.26 This
study has been completed, but the results are not yet
published. All of these clinical studies have investigated
the effect of MRA therapy initiated after reperfusion has
taken place, and therefore only target post-MI LV remod-
eling. None of these clinical studies have investigated the
effect of targeting myocardial reperfusion injury with MRA
therapy.
Whether early intravenous MRA therapy administered
prior to reperfusion followed by 3 months of oral MRA
therapy can reduce MI size and reduce adverse LV
remodeling is not known and will be investigated in the
MINIMISE-STEMI trial.
Conclusion
By administering the MRA therapy prior to reperfusion,
we hope to target myocardial reperfusion injury and obtain
additional benefit in terms of MI size reduction, which
will hopefully add to the known beneficial effects of oral
MRA therapy in terms of preventing post-MI adverse LV
remodeling.
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